Clinical application of a glucoside-hydrolase inhibitor (Bay g 5421) to patients with hyperlipidemia and maturity-onset type diabetes mellitus.

Publisher Website
Google Scholar
Abstract
Administration of Bay g 5421 [O-[4,6-dideoxy-4-[[1S-(1,4,6/5)-4,5,6-trihydroxy-2-cyclohexen-1-yl]amino]-.alpha.-D-gluco pyranosyl]-(1 .fwdarw. 4)-O-.alpha.-D-glucopyranosyl-(1 .fwdarw. 4)-D-glucopyranose], a glucoside-hydrolase inhibiting oligosaccharide, decreased the elevation of blood glucose and plasma insulin after test meal ingestion in 2 healthy volunteers by delaying the rate of the starch absorption estimated by the serial breath H2 analysis. The clinical trial was conducted on 9 hyperlipidemic patints and 6 diabetic patients with a daily dosage of 300 mg of Bay g 5421 for 4 wk. A significant decrease in plasma triglyceride and total cholesterol was observed in both hyperlipidemics and diabetics, while their body weight remained mostly unchanged. Both mild glucose intolerance and markedly increased insulin response during oral glucose tolerance test in the hyperlipidemics were significantly ameliorated after Bay g 5421 trial, but the diabetic glucose intolerance and blunted insulin secretion did not change significantly in the diabetics after the trial. Bay g 5421 seems to be the compound that is clinically more beneficial in hyperlipidemia than in diabetes mellitus.